Trials / Completed
CompletedNCT06662825
Real World Patient Characteristics and Treatment Patterns From Crizanlizumab Use: Preliminary Analysis From Select Sickle Cell Centers
SEG-2022-01 Patient Characteristics and Treatment Patterns From Early Crizanlizumab Use in Real-world Setting: Preliminary Analysis From Select Sickle Cell Centers
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 376 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
This was a retrospective cohort study using secondary data from member sites of the National Alliance of Sickle Cell Centers (NASCC) with patients who had initiated crizanlizumab between 2019 and 2022.
Conditions
Timeline
- Start date
- 2022-12-13
- Primary completion
- 2023-11-01
- Completion
- 2023-11-01
- First posted
- 2024-10-29
- Last updated
- 2024-10-29
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT06662825. Inclusion in this directory is not an endorsement.